Imperial College London
Alternate

Professor Sir Roy Anderson FRS, FMedSci

Faculty of Medicine, School of Public Health

Professor in Infectious Disease Epidemiology
 
 
 
//

Contact

 

roy.anderson Website

 
 
//

Assistant

 

Mrs Clare Mylchreest +44 (0)7766 331 301

 
//

Location

 

LG35Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kura:2020:10.1186/s13071-020-04409-3,
author = {Kura, K and Hardwick, RJ and Truscott, JE and Toor, J and Hollingsworth, TD and Anderson, RM},
doi = {10.1186/s13071-020-04409-3},
journal = {Parasites and Vectors},
pages = {1--10},
title = {The impact of mass drug administration on Schistosoma haematobium infection: what is required to achieve morbidity control and elimination?},
url = {http://dx.doi.org/10.1186/s13071-020-04409-3},
volume = {13},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Schistosomiasis remains an endemic parasitic disease causing much morbidity and, in some cases, mortality. The World Health Organization (WHO) has outlined strategies and goals to combat the burden of disease caused by schistosomiasis. The first goal is morbidity control, which is defined by achieving less than 5% prevalence of heavy intensity infection in school-aged children (SAC). The second goal is elimination as a public health problem (EPHP), achieved when the prevalence of heavy intensity infection in SAC is reduced to less than 1%. Mass drug administration (MDA) of praziquantel is the main strategy for control. However, there is limited availability of praziquantel, particularly in Africa where there is high prevalence of infection. It is therefore important to explore whether the WHO goals can be achieved using the current guidelines for treatment based on targeting SAC and, in some cases, adults. Previous modelling work has largely focused on Schistosoma mansoni, which in advance cases can cause liver and spleen enlargement. There has been much less modelling of the transmission of Schistosoma haematobium, which in severe cases can cause kidney damage and bladder cancer. This lack of modelling has largely been driven by limited data availability and challenges in interpreting these data. RESULTS: In this paper, using an individual-based stochastic model and age-intensity profiles of S. haematobium from two different communities, we calculate the probability of achieving the morbidity and EPHP goals within 15 years of treatment under the current WHO treatment guidelines. We find that targeting SAC only can achieve the morbidity goal for all transmission settings, regardless of the burden of infection in adults. The EPHP goal can be achieved in low transmission settings, but in some moderate to high settings community-wide treatment is needed. CONCLUSIONS: We show that the key determinants of achieving the WHO goals are the precise form of the ag
AU  - Kura,K
AU  - Hardwick,RJ
AU  - Truscott,JE
AU  - Toor,J
AU  - Hollingsworth,TD
AU  - Anderson,RM
DO  - 10.1186/s13071-020-04409-3
EP  - 10
PY  - 2020///
SN  - 1756-3305
SP  - 1
TI  - The impact of mass drug administration on Schistosoma haematobium infection: what is required to achieve morbidity control and elimination?
T2  - Parasites and Vectors
UR  - http://dx.doi.org/10.1186/s13071-020-04409-3
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33203467
UR  - https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-020-04409-3
UR  - http://hdl.handle.net/10044/1/84562
VL  - 13
ER  -
Download